Raymond James Financial Services Advisors Inc. disclosed to the Securities and Exchange Commission (SEC) in its most recent filing that during the third quarter of 2018, the company increased its holdings in CRISPR Therapeutics AG (NASDAQ: CRSP) by 26.5%. The institutional investor’s stock holdings in the company now total 26,280 shares, following the acquisition of an additional 5,498 shares during the preceding quarter. This brings the total number of shares held in their investment portfolio to 26,280. The most recent disclosure that Raymond James Financial Services Advisors Inc. made with the SEC indicated that the value of the company’s holdings in CRISPR Therapeutics was $1,717,000. The company provided this information.
Other institutional investors and hedge funds, including a number of them, have also made adjustments to the proportion of their CRSP holdings that they currently have. During the second quarter, Allworth Financial LP achieved a 21.0% increase in the proportion of CRISPR Therapeutics shares it owned. Allworth Financial LP now has a total of 737 shares, valued at $45,000, after purchasing an additional 128 shares during the preceding quarter. Allworth Financial LP purchased these shares. In the second quarter, Steward Partners Investment Advisory LLC increased 8.2% in the percentage of CRISPR Therapeutics shares it owned, bringing its total ownership to 100%. After making an additional purchase of 148 shares during the most recent quarter, Steward Partners Investment Advisory LLC now owns 1,944 shares of the company, which have a value of $118,000 after taking recent market activity into account (up from 1,880). During the second quarter, HC Advisors LLC completed a 2.1% increase in the proportion of CRISPR Therapeutics stock that it held. After acquiring 154 additional shares during the most recent fiscal quarter, HC Advisors LLC now holds 7,432 shares. The current market price for each share is $452.00, giving the investment a total value of $452,000. During the third quarter, Bouvel Investment Partners LLC increased the proportion of CRISPR Therapeutics stock owned by one-hundredth of one percent. Following the acquisition of an additional 190 shares of the company’s stock during the most recent quarter of the fiscal year, Bouvel Investment Partners LLC now holds a total of 18,726 shares of the company’s stock, which have a value of $1,224,000. During the second quarter, Cetera Investment Advisers increased the amount of CRISPR Therapeutics stock owned by 3.0%, making this the last and most important point. Cetera Investment Advisers now owns 8,064 shares valued at $490,000. This is a result of the purchase of 237 additional shares in the company during the most recent fiscal quarter. Institutional investors and hedge funds jointly own 71.51% of the total number of shares in the company, making up the majority of the shareholders.
In recent weeks, various research companies have shown a rise in interest in CRSP. Recent Acquisitions made by the EF Hutton Company On Thursday, January 5, I embarked upon the process of beginning to compose an article that will be focused on the therapeutic applications of CRISPR. They recommended that the company “buy” the stock and establish a price objective of $75.00. Barclays stated its intention to lower its price estimate for CRISPR Therapeutics from $800.00 to $61.00 in a research report published on November 2. Citigroup assigned a “neutral” rating to CRISPR Therapeutics in a research note published on November 23, and the company lowered its price goal from $800.00 to $600.00. The price target had been set at $80 in the past. SVB Leerink gave CRISPR Therapeutics an “outperform” rating in a research report published on Monday, November 7.
Due to this rating, the firm increased its price objective for the company from $75.00 to $76.00. Credit Suisse Group announced on November 2 in a research note published that day. In the note, they said they would lower their target price for CRISPR Therapeutics from $90.00 to $780.00. Nine research analysts advise buying the stock, six others advise keeping their current position, and two industry professionals advise selling the share. According to Bloomberg.com, most analysts have given the company a “Hold” rating, and their stock price objective is $99.88. This information comes from the website’s survey of those analysts.
The NASDAQ: CRSP stock started the trading day on Thursday for $50.55. The company has a PE ratio of -5.74 and a beta of 1.77; its market value is currently at $3.96 billion. The share has traded at an average moving price of $50.01 over the past 50 trading days, while the moving average price over the last 200 trading days has been $61.26. During the last year, the price of a share of CRISPR Therapeutics AG has ranged from as low as $38.94 to as high as $86.95.
CRISPR Therapeutics (NASDAQ: CRSP) informed the public about its findings by publishing a report on November 1, which was made available to the public. The company announced that its earnings per share (EPS) for the period came in at $2.24, which was $0.06 higher than the average analyst projection of $2.30. The company only brought in $0.09 million in revenue for the quarter, a far cry from the $3.53 million in sales predicted by industry experts for the period in question. CRISPR Therapeutics’ net margin and return on equity were in the red, with the former coming in at a negative 4,831.79% and the latter coming in at a negative 31.34%. There is a general agreement among those who follow the market that CRISPR Therapeutics AG will report a loss of -9.23 cents per share for 2018.
Samarth Kulkarni, the Chief Executive Officer of CRISPR Therapeutics, sold 25,000 of the company’s shares of stock on October 26. This news comes as part of a series of recent developments concerning the company. A total of $1,370,250.00 was received for the sale of the shares, which works out to a price of $54.81 per share on average. After the completion of the sale, the Chief Executive Officer now directly owns 290,279 shares of the company, and the total value of those shares is approximately $15,910,191.99. A document containing the information given to the Securities and Exchange Commission regarding the transaction can be found on this website. The document contains all of the information that was given to the SEC. Over the most recent three months, the purchase and subsequent sale of 75,000 company stock by company insiders have resulted in total revenue of $3,744,250. The company’s management and employees hold a stake in the business equivalent to 5.30 percent of the total number of shares outstanding.
CRISPR Therapeutics is a gene-editing company that has developed its own CRISPR/Cas9 platform to create innovative gene-based medicines to treat incapacitating diseases. These therapies are geared toward enhancing the patient’s quality of life in some way. The ground-breaking method of gene editing known as CRISPR/Cas9 makes it possible to make changes to genomic DNA that are accurate and specific to a particular location. CRISPR Therapeutics has established a therapeutic pipeline for a wide range of diseases. Some of the disease categories included in this list are hemoglobinopathies, cancer, regenerative medicine, and rare diseases. These are just some of the disease categories included in this list.
